Receptor-Binding Domain (Beta Variant) (SARS-CoV-2) (RBD (Beta Variant))

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a critical region responsible for binding to the host cell receptor, angiotensin-converting enzyme 2 (ACE2), facilitating viral entry into human cells. The Beta variant, also known as lineage B.1.351 or 501Y.V2, was first identified in South Africa and is classified as a Variant of Concern due to its increased infectivity and ability to evade immune responses. The RBD encompasses amino acids 319–541 of the spike glycoprotein and contains three key mutations: K417N, E484K, and N501Y. These mutations alter the structure and stability of the RBD, affecting both ACE2 binding affinity and antibody recognition, leading to enhanced infectivity and reduced neutralization by some antibodies.

Other names

Spike RBD (Beta Variant)B.1.351 RBD501Y.V2 RBD

N/A